Neurogene (NASDAQ:NGNE) Stock Price Expected to Rise, Robert W. Baird Analyst Says

Neurogene (NASDAQ:NGNE) had its price objective lifted by analysts at Robert W. Baird from $54.00 to $72.00 in a research note issued on Tuesday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Robert W. Baird’s target price points to a potential upside of 81.54% from the company’s current price.

Separately, HC Wainwright decreased their target price on Neurogene from $51.00 to $49.00 and set a “buy” rating for the company in a research report on Monday, August 12th. Eight equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $63.33.

Neurogene Trading Down 0.9 %

Shares of NASDAQ NGNE opened at $39.66 on Tuesday. Neurogene has a 1 year low of $12.49 and a 1 year high of $74.49. The company’s 50-day moving average is $46.91 and its 200 day moving average is $40.12.

Hedge Funds Weigh In On Neurogene

Several institutional investors and hedge funds have recently modified their holdings of NGNE. MetLife Investment Management LLC purchased a new stake in Neurogene during the 3rd quarter valued at about $254,000. BNP Paribas Financial Markets lifted its stake in shares of Neurogene by 192.8% in the third quarter. BNP Paribas Financial Markets now owns 2,170 shares of the company’s stock worth $91,000 after buying an additional 1,429 shares in the last quarter. FMR LLC lifted its stake in shares of Neurogene by 912.4% in the third quarter. FMR LLC now owns 731,801 shares of the company’s stock worth $30,706,000 after buying an additional 659,515 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Neurogene by 2.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 30,317 shares of the company’s stock valued at $1,272,000 after buying an additional 741 shares during the last quarter. Finally, Jennison Associates LLC bought a new stake in shares of Neurogene during the third quarter valued at approximately $3,300,000. 52.37% of the stock is currently owned by institutional investors.

Neurogene Company Profile

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.